News

Deal Announcements

Dicerna Pharma Secures Third Venture Capital Round

Friday, August 2, 2013 5:58:00 AM PDT | VentureDeal
Watertown, Massachusetts  --  Dicerna Pharmaceuticals has received commitments of $60 million for its Series C round of institutional venture capital financing.

Dicerna is developing therapeutics based on Dicer substrate technology, making use of the RNA interference mechanism.

RA Capital led the round, which included Brookside Capital, Deerfield Capital, Omega Funds, Domain Associates, Oxford Bioscience Partners, Skyline Ventures, Abingworth Management and SR One.

The company will use the proceeds from the financing to advance multiple drug programs.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1